

STUDIES OF DIPYRONE (METAMIZOLE SODIUM) TOXICITY IN AVIAN SPECIES

Asif Farooq Awan*, Muhammad Ashraf**, Owais Umer**, Taha Nazir***,
Muhammad Shoaib Akhtar***, Habib Ur Rehman**

*EDO Office - Mandi Baha Uddin, Health Department, Punjab, Pakistan.

** Faculty of Bio-Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan.

*** Deptt. of Pharmacy, University of Sargodha, Sargodha 40100 Pakistan

ABSTRACT

The anti-pyretic and analgesic effects of dipyron are similar to those of the other drugs but its toxicity differs significantly. Despite of sharing clinical usefulness, dipyron share several unwanted side effects, the most common is a propensity to induce sudden and unidentified emergency that can sometimes result into death of patient (Gabriel *et al.*, 1991). Which restrict its prescription in human, poultry and veterinary practice. Thus it is needed to study dipyron to prevent causalities, find out toxicity and reduce angiogenic factor in clinical practice. We therefore aimed to determine toxicity of dipyron to assure the safety of wild life. Different toxic levels of dipyron were administered intra-muscularly to broiler chicks for four days. Feed and water were provided *ad libitum*. A record of physical examination, signs of toxicity and mortality rate in each group was maintained. Blood samples were drawn before and after medication for examination of AST, ALT, Uric Acid, Alkaline phosphatase and Creatinine. Finally, postmortem examination was performed to confirm tissues damages. Based on the necropsy findings and biochemical analysis, it could be suggested to dipyron in the avian species. Keeping in view the environmental problem; vultures crises, veterinary causalities, it is conceivable that dipyron exerts desirable pharmacological effects in human medicine and may be used instead of diclofenac sodium in veterinary and poultry practices.

Keywords: Dipyron (metamizole sodium) toxicity, Broiler birds, LFT's

Address for correspondence: Prof. Dr. Muhammad Shoaib Akhtar, Department of Pharmacy, University of Sargodha, Sargodha 40100 Pakistan. Email: drmsakhtar@gmail.com

Introduction

Methane sulfonic acid sodium mono hydrate ($C_{13}H_{16}N_3NaO_4S.H_2O$), Dipyron or metamizole sodium is used as an analgesic and antipyretic agent. It has also been widely used by equine practitioners to treat equine colic and other conditions of gastrointestinal spasm or hypermotility in both small and large animals (Gray and Yano, 1975). Today the efficacy of dipyron in certain spasmodic conditions in small and large animals is controversial (Lowe 1969; Gray and Yano 1975). According to Lowe (1969), dipyron is valueless as an analgesic in the treatment of equine colic. It also has no effect on spontaneous intestinal motility or upon intestinal spasms produced by nerve stimulation, cholinergic drugs, ganglionic stimulant drugs, histamine, or morphine (Gray and Yano 1975). Conversely, the drug does antagonize bradykinin-induced intestinal spasms as do other members of the pyrazolon class of compounds. It is contraindicated in food-producing animals, including lactating dairy animals. Dipyron can interfere with, or mask the presence of prohibited drugs in race animals for 5 days after its use (Bierhaus 1970). This would indicate that the drug should not be used in racing animals for at least 5 days prior to a race event. Moreover, recent information indicates that the use of dipyron with chlorpromazine can result in serious hypothermia and it also has a tendency to increase bleeding, due to the suppression of the formation of prothrombin (Woodbury and Fingl 1975). Because of this contradictory discussion, we have aimed this project to evaluate the therapeutical credibility of metamizole sodium.

Therapeutical hazards of metamizole demand its re-evaluation to assure the safety of avian species being hazardous to wild life. Especially the already reported vulture crises and veterinary emergencies have increased the value of this project. Thus, it is direly need to find out a suitable replacement of diclofenac, prevent renal toxicity, induce tumor apoptosis and reduce angiogenic factor in veterinary practice.

Materials and Methods

The experiment was conducted at experimental sheds of the Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences, Lahore. A total of 225, day old broiler chicks collected from the "Pakistan Hatchery" were vaccinated according to the vaccination schedule given in Table 1. The dipyrone (Metamizole sodium) injection 250 mg/ml was obtained from Orient labs. Pvt. Limited.

Table 1. Vaccination schedule.

| Age | Vaccine | Route of Vaccination |
|----------------------|-------------------|----------------------|
| 6 th day | Newcastle disease | Eye drop |
| 15 th day | Gumboro (I.B.D) | Drinking water |
| 21 st day | Newcastle disease | Drinking water |
| 25 th day | Gumboro (I.B.D) | Drinking water |

Experimental design

On 28th day 75 birds were randomly divided into 2 groups comprising; Group A with 50 and B with 25 birds. On 29th day metamizole I/M 50mg/kg body weight injected for twice a day upto four days individually to each bird of group A, for four consecutive days. Group B was kept as control. The remaining 75 birds were divided into two groups C with 75 and D with 25 birds. Each bird of group C was injected metamizole I/M 100 mg/kg body weight for twice a day upto four days and group D was kept as control group and no medication given to them. Findings are have been summarized Table-5. Feed and water was provided *ad libitum*. A daily basis record of physical examination, sign and symptoms and toxicity was maintained regularly.

Sample schedule and parameters determined

Three ml blood sample from birds of each group (A, B, C and D) was collected before the start of medication on 29th day. Then blood sample from the same birds were drawn from wing vein (vena cutanea ulnaris) on days 33, 37 and 41 after medication for determination of serum values of following parameters; Aspartate Transaminase (Thomas, 1998), Alanine Transaminase (Thomas, 1998), Uric acid, Alkaline phosphatase (ALP) (Bessey *et al.*, 1946), Concentration of creatinine in serum (Tietz, 1986)

Clinical findings and statistical analysis

The clinical findings mortality and postmortem was recorded during experimental period. The collected data were analyzed statistically with one way analysis of variance (Steel et. Al., 1982). On days 41st and 47th postmortem were done. Three parameters including postmortem, liver, kidney biopsies and stainings were examined.

Results

After completion of study, results colleted are given below. Groups B and D were kept control, as no medication was given to them and their findings are summarized in Table-6.

As shown in table 3 (a) the mean values of uric acid of metamizole sodium or dipyrone was 5.945620 mg/dl, 5.669880 mg/dl, 6.552200 mg/dl and 5.847080 mg/dl at before medication, 1st day after medication, 5th and 9th day after medication respectively. There was no significant difference in the mean values of uric acid of dipyrone table-3 (b).

The mean values of creatinine in metamizole sodium group was 1.387720 mg/dl, 1.247820 mg/dl, 1.411000 mg/dl and 1.101740 mg/dl at before medication, 1st day after medication, 5th and 9th day after

medication respectively table-3 (a). There was no significant difference in the mean values of creatinine of metamizole sodium table-3 (b).

As shown in table 3 (a) the mean values of alanine transaminase of metamizole sodium group was 10.328800 μL , 6.962000 μL , 10.556020 μL and 14.332860 μL at before medication, 1st day after medication, 5th and 9th day after medication respectively table-3 (b). There was significant difference in the mean values, of alanine transaminase of metamizole sodium table-3 (b).

As shown in table 3 (a) the mean values of aspartate transaminase of metamizole sodium was 173.64524 μL , 225.46830 μL , 217.304000 μL and 218.45800 μL at before medication, 1st day after medication, 5th and 9th day after medication respectively. There was significant difference in the mean values of aspartate transaminase of metamizole sodium table-3 (b).

As shown in table 3 (a) the mean values of alkaline phosphatase of metamizole sodium was 28.618000 μL , 48.470000 μL , 51.012000 μL and 47.072000 μL at before medication, 1st day after medication, 5th and 9th day after medication. There was significant difference in the mean values of alkaline phosphatase of metamizole sodium table-3 (b).

Table-3 (a): Various biochemical parameters of Dipyrone group n=5 values given as mean \pm SEM

| Uric Acid mg/dl | Creatinine mg/dl | ALT μL | AST μL | ALP μL | Time of sample collection |
|---------------------------|------------------------------|---------------------------|------------------------------|-----------------------------|--------------------------------------|
| 5.9456200 \pm 363993 | 1.387720 \pm 162545 | 10.328800 \pm 953864 | 173.64524 \pm 11.240398 | 28.618000 \pm 1.484148 | Before medication |
| 5.669880 \pm 146420 | 1.247820 \pm 108414 | 6.962000 \pm 712966 | 225.46830 \pm 12.117352 | 48.470000 \pm 977369 | 1 st day after medication |
| 6.552200 \pm 378473 | 1.411000 \pm 9.941EE-02 | 10.556020 \pm 709688 | 217.30400 \pm 13.145889 | 51.012000 \pm 924751 | 5 th day after medication |
| 5.847080 \pm 256815 | 1.101740 \pm 7.530E-02 | 14.332860 \pm 984038 | 218.45800 \pm 13.156353 | 47.072000 \pm 886304 | 9 th day after medication |

Table-3 (b): ANOVA of Dipyrone

| | | Sum of Squares | Df | Mean Square | F | Sig. |
|------------|----------------|----------------|----|-------------|--------|------|
| Uric acid | Between groups | 2.201 | 3 | .734 | 1.616 | .225 |
| | Within groups | 7.263 | 16 | .454 | | |
| | Total | 9.463 | 19 | | | |
| Creatinine | Between groups | .307 | 3 | .102 | 1.523 | .247 |
| | Within groups | 1.075 | 16 | 6.716E-02 | | |
| | Total | 1.381 | 19 | | | |
| ALT | Between groups | 136.163 | 3 | 45.388 | 12.563 | .000 |
| | Within groups | 57.803 | 16 | 3.613 | | |
| | Total | 193.966 | 19 | | | |
| AST | Between groups | 8396.290 | 3 | 2798.763 | 3.617 | .036 |
| | Within groups | 12381.615 | 16 | 773.851 | | |
| | Total | 20777.906 | 19 | | | |
| ALP | Between groups | 1575.104 | 3 | 525.035 | 87.531 | .000 |
| | Within groups | 95.973 | 16 | 5.998 | | |
| | Total | 1671.077 | 19 | | | |

Various biochemical parameters in control group

No medication was given to control group

As shown in table 5 (a) the mean values of uric acid of normal or control bird was 5.031800 mg/dl, 4.776720 mg/dl, 5.479140 mg/dl and 4.874880 mg/dl at 1st, 5th and 9th day. There was no significant difference in the mean values of uric acid of control birds table-5 (b).

The mean values of creatinine in control birds was 1.052080 mg/dl, 0.972660 mg/dl, 1.134440 mg/dl and 1.066040 mg/dl at 1st, 5th and 9th day. There was no significant difference in the mean values of creatinine in control birds table-5 (b).

As shown in table 5 (a) the mean values of alanine transaminase of control birds was 10.149740 μL , 10.205000 μL , 10.269660 μL and 10.351780 μL at 1st, 5th and 9th day. There was no significant difference in the mean values of ALT in control birds table-5 (b).

As shown in table 5 (a) the mean values of aspartate transaminase of control birds was 193.55568 μL , 199.43520 μL , 158.98660 μL and 166.81000 μL . There was no significant difference in the mean values of aspartate transaminase of control birds table-5 (b).

Table-5 (a): Various biochemical parameters of normal group n=5 values given as mean± SEM

| Uric Acid mg/dl | Creatinine mg/dl | ALT μ /L | AST μ /L | ALP μ /L | Time of sample collection |
|----------------------|---------------------|-----------------------|-------------------------|------------------------|---------------------------|
| 5.031800 ±.209874 | 1.052080 ±3.172E-02 | 10.149740 ±.687521 | 193.55568 ±2.584983 | 27.252000 ±1.187440 | 0 day |
| 4.776720 ±.474997 | 0.972669 ±6.390E-02 | 10.205000 ±.376771 | 199.43520 ±18.580837 | 34.470000 ±3.520395 | 1 st day |
| 5.479140 ±.400607 | 1.134440 ±9.002E-02 | 10.269660 ±.401202 | 158.98660 ±16.616974 | 33.548000 ±3.204323 | 5 th day |
| 4.874880 ±.152974 | 1.066040 ±9.043E-02 | 10.351780 ±.507856 | 166.81000 ±10.338517 | 27.824400 ±1.302525 | 9 th day |

As shown in table 5 (a) the mean values of alkaline phosphatase of piroxicam was 27.252000 μ /L, 34.470000 μ /L, 33.548000 μ /L and 27.824400 μ /L. There was no significant difference in the mean values of alkaline phosphatase of control birds table- 5(b).

Table-5 (b): ANOVA of normal

| | | Sum of Squares | Df | Mean Square | F | Sig. |
|------------|----------------|----------------|----|-------------|-------|------|
| Uric acid | Between groups | 1.447 | 3 | .482 | .851 | .486 |
| | Within groups | 9.071 | 16 | .567 | | |
| | Total | 10.519 | 19 | | | |
| Creatinine | Between groups | 6.607E-02 | 3 | 2.202E-02 | .824 | .499 |
| | Within groups | .427 | 16 | 2.671E-02 | | |
| | Total | .493 | 19 | | | |
| ALT | Between groups | .113 | 3 | 3.780E-02 | .029 | .993 |
| | Within groups | 20.670 | 16 | 1.292 | | |
| | Total | 20.784 | 19 | | | |
| AST | Between groups | 5883.275 | 3 | 1961.092 | 2.135 | .136 |
| | Within groups | 14698.768 | 16 | 918.673 | | |
| | Total | 20582.043 | 19 | | | |
| ALP | Between groups | 212.301 | 3 | 70.767 | 2.197 | .128 |
| | Within groups | 515.349 | 16 | 32.209 | | |
| | Total | 727.650 | 19 | | | |

Results of necropsy findings of experimental chicks

The birds were slaughtered at the end of experiment and different lesions in kidney, liver and muscles were recorded. Each bird of group B was injected I/M Dipyron 50 mg/kg body weight for twice a day upto four days. Each bird of group C was injected I/M Dipyron 100 mg/kg body weight for twice a day upto four days. Findings are mentioned in table-6. Groups B and C were kept control no medication given to them and group 0 was kept control no medication given to them. Findings are mentioned in table-6.

Table-6: Result of necropsy findings of various drugs in broilers chicks

| Drug | Dose | Postmortem lesions | | |
|---------|-------------------------|--------------------|-------|--------|
| | | Site of injection | Liver | Kidney |
| Dipyron | 50 mg/kg n = 15 | 0/15 | 3/15 | 0/15 |
| | 100 mg/kg n = 15 | 4/15 | 6/15 | 0/15 |
| Control | No medication n = 15 | 0/15 | 0/15 | 0/15 |
| | No medication n = 15 | 0/15 | 0/15 | 0/15 |

Discussion

Postmortem findings revealed that there were no hepatic or renal abnormalities moreover no muscle necrosis was observed at the injection site at the dosage rate of 1 mg/kg while muscle necrosis was observed in few birds at the dosage rate of the 2 mg/kg and the liver and kidneys were normal at the stated dose. The biochemical analysis showed that there was no change in serum uric acid, creatinine, ALT and AST levels in the samples collected at different times during experiment but there was significant difference in the values of ALP in the samples collected before and after medication which may be due to biliary obstructions Embert H., 1986).

It has been reported that when diclofenac sodium treated carcasses were eaten by the vultures, heavy mortality was noted due to acute renal failure caused by severe visceral gout (Oaks *et al.*, 2004). Therefore a suitable replacement of diclofenac sodium was needed in veterinary practice. Taking this into account the present project was designed to study the toxicity of dipyron to explore the non-hazardous drug to safe wild life.

Roelvink *et al.*, (1991) evaluated the analgesic and spasmolytic effects of dipyron (Novalgine) I/V 2500 mg/100 kg body weight in a balloon-induced model of colic, using five ponies with caecal fistulae. Dipyron had a good analgesic effect in only two of the ponies, starting after eight to 10 minutes and lasting for 50 minutes.

Zentella de Pina *et al.*, (1993) assayed dipyron to search its capability in preventing the hepatic increase of triacylglycerols and thiobarbituric acid reactive substances, as an indication of lipid peroxidation, resulting from the acute intoxication of rats with ethanol. It was concluded that the dipyron contributed to controlling hepatic lipid peroxidation, and hence the oxidative stress promoted by ethanol intoxication.

Espiridiao *et al.*, (1996) studied the morphological and biochemical action of dipyron on the placenta of albino rats by means of karyometry of trophoblastic giant cells and by determinations of DNA, RNA and total protein contents. Karyometric results showed that the nuclear volumes of placental cells in rats treated with dipyron during the first 3 periods were significantly greater than in control animals

Postmortem findings of the birds treated with dipyron revealed hepatic lesions as focal necrosis. The kidneys of these birds were found normal at the doses rate of 50 mg/kg body weight. The lesions were severe when dose was increased to 100 mg/kg body weight. Necrotic lesions in the muscles at the site of injection were observed in few birds. The serum uric acid and creatinine level remained unchanged during experiment indicating that there was no damage to the kidneys. The results of this study are in accordance with Farker *et al.*, (1995) and Espiridiao *et al.*, (1996) who reported that dipyron has no effect on renal clearance of creatinine.

There was significant difference in the values of serum level of ALT, AST and ALP, which indicated liver damage as observed in postmortem findings. The postmortem of the control group revealed no abnormalities particularly in liver, kidneys and muscles. Similarly there was no significant difference in the serum values of uric acid and creatinine ALT, AST and ALP in the samples collected at the different times during experiments in the group.

Thus it is concluded that dipyron is comparatively non-toxic in avian species. No mortality was recorded in all groups. Based on the necropsy findings and biochemical analysis it was found that dipyron was safest drug. More over, the toxicity based ranking of dipyron shows comparative better position to control pyrexia and inflammation in poultry and veterinary practice. Keeping in view the environmental problem (vultures crises) it is also recommended to prescribe dipyron that has good pharmacological effects in human medicine may be used instead of diclofenac sodium in clinical practice.

References

- 1 Bessey, O. A., O. H. Lowry and M. J. Brock, 1946. Method for the determination of alkaline phosphatase. J. Biol. Chem., 164:321.
- 2 Bierhaus, G. M. 1970. Modern medicine and testing. Proc. Am. Assoc. Equine Pract. p. 199.
- 3 Embert H. Coles 1986. Veterinary Clinical Pathology. 4th Edition, Nueva Editorial Interamericana, C-6450 Mexico.
- 4 Gabriel, S.E., L. Jaakkimainen, and C. Bombardier 1991. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med., 115: 787-796.
- 5 Espiridiao, S., R. M. Oliveira-Filho, A. Doine, M. J. Simoes, G. R. Focchi, J. Evencio Neto, B. I. Kopelman and L. Kulay Junior 1996. Morphological and biochemical action of dipyron on rat placenta. Gen. Pharmacol. 27(3): 505-507.

- 6 **Farker, K., N. Nassr, F. Huck, G. Zerle, B. Rosenkranz, G. Schmieder and A. Hoffmann** 1995. Dipyrrone and diclofenac do not influence creatinine-clearance, inulin-clearance or PAH-clearance in healthy male volunteers. *Int. J. Clin. Pharmacol Ther.* 33(3): 125-130.
- 7 **Lowe, J. E.** 1969. Pentazocine (Talwin-V) for the relief of abdominal pain in ponies-A comparative evaluation with description of a colic model for analgesia evaluation. *Proc. Am. Assoc. Equine Pract.*, p. 31.
- 8 **Oaks, J. L., M. Gilbert, M. Z. Virani, R. T. Watson, C. U. Meteyer, B. A. Rideout, H. L., Shivaprasad, S. Ahmed, M. J. I. Chaudry, M. Arshad, S. Mahmood, A. Ali and A. A. Khan** 2004. Diclofenac residues as the cause of population decline of vultures in Pakistan. *NATURE* 2317-19/1/2004-VBICKNELL-93380.
- 9 **Roelvink, M. E., L. Goossens, H. C. Kalsbeek and T. Wensing** 1991. Analgesic and spasmolytic effects of dipyrrone, hyoscine-N-butylbromide and a combination of the two in ponies. *Vet. Rec.* 129(17): 378-80.
- 10 **Steel, R. G. D. and J. H. Torries** 1982. *Principal and Procedures of Statistics*, 2nd Edi., McGraw Hill International Book Company, Tokyo, Japan.
- 11 **Tietz, N. W.** 1986. Kinetic method of deproteinization *Text book of Clinical Chemistry*, W. B. Saunders: 1271.
- 12 **Thomas, L.** 1998. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) In: Thomas L., Editor. *Clinical Laboratories Diagnostics*, 1st Edi. Frankfurt: TH-Boos Verlagsgesellschaft; p. 55-65 and 208-214.
- 13 **Zentella de Pina, M., S. Corona, A. E. Rocha-Hernandez, Y. Saldana Balmori, G. Cabrera and E. Pina** 1994. Restoration by piroxicam of liver glutathione levels decreased by acute ethanol intoxication. *Life Sci.* 54(19): 1433-9.